![](/img/cover-not-exists.png)
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
Jakubowiak, Andrzej J., Houisse, Ivan, Májer, István, Benedict, Ágnes, Campioni, Marco, Panjabi, Sumeet, Ailawadhi, SikanderLanguage:
english
Journal:
Expert Review of Hematology
DOI:
10.1080/17474086.2017.1391088
Date:
October, 2017
File:
PDF, 2.18 MB
english, 2017